GiVE 2: Increasing access to CBT for psychosis patients

  • Research type

    Research Study

  • Full title

    Increasing access to CBT for psychosis patients: a feasibility, randomized controlled trial evaluating brief, targeted CBT for distressing voices delivered by Assistant Psychologists

  • IRAS ID

    255920

  • Contact name

    Mark Hayward

  • Contact email

    Mark.Hayward@sussexpartnership.nhs.uk

  • Sponsor organisation

    Sussex Partnership NHS Foundation Trust

  • ISRCTN Number

    ISRCTN16166070

  • Duration of Study in the UK

    1 years, 7 months, 30 days

  • Research summary

    Psychosis is a type of mental health problem. People with psychosis usually experience distressing delusional beliefs and/or voice hearing. The National Institute for Health & Care Excellence (NICE) recommends Cognitive Behaviour Therapy (CBT) as one of the best treatments for psychosis. But only 10% of people with psychosis have the chance to receive CBT. CBT is scarce because it can be quite long and needs to be delivered by highly trained therapists. We want to see if a shorter version of CBT that is delivered by therapists with less training will be helpful for people who hear voices. Our research aims to give more people with psychosis the chance to receive a helpful talking therapy.

    Participants of the study will be psychosis patients in NHS community secondary care adult mental health services who are currently experiencing distressing voice hearing.

    The study will run over two sites: (1) Sussex Partnership Trust and (2) Pennine Care NHS Foundation Trust.

    The study will recruit 90 people with psychosis who will be randomly be allocated into one of three groups; (1) 30 participants will receive 8 sessions of Guided self-help CBT intervention for distressing VoicEs (GiVE) (2) 30 participants will receive 8 sessions of Supportive Counselling that is not specifically about hearing voices (3) 30 participants will continue with their usual care. Participants will be enrolled in the study for 28 weeks in total.

    This is a feasibility study. Our findings will tell us if it is possible to run a larger version of this study. We will only find out if the therapy works when we run this larger study.

  • REC name

    London - Surrey Research Ethics Committee

  • REC reference

    18/LO/2091

  • Date of REC Opinion

    23 Jan 2019

  • REC opinion

    Further Information Favourable Opinion